Next Generation Cardiac Biomarker From Critical Diagnostics Accurately Predicts Risk of Heart Failure in the General Population  
11/8/2012 10:25:38 AM

SAN DIEGO--(BUSINESS WIRE)--Critical Diagnostics, makers of the PresageĀ® ST2 Assay, announced today that during a presentation at the American Heart Association Scientific Sessions in Los Angeles, the results of a study conducted through the Mayo Clinic and Foundation, Plasma Levels of ST2 in the Community: Association with cardiac remodeling, heart failure incidence and mortality, highlighted the remarkable accuracy of ST2 in predicting the risk of heart failure and mortality in the general population.